Spinal administration of opioid and a 2 -adrenergic receptor (a 2 AR) agonists produces analgesia, and agonists interact synergistically when coadministered. The molecular mechanism underlying this synergy is largely unknown. Pharmacological studies have identified both the delta and the mu-opioid receptors (DOR and MOR) as candidate receptors capable of interacting synergistically with a 2 AR agonists. However, recent studies attribute the antinociceptive effect of DOR agonists to actions at the MOR, calling the role of DOR in opioid-adrenergic synergy into question. Other studies suggesting that DOR is implicated in morphine antinociception raise the possibility that DOR is nonetheless required for morphine synergy with a 2 AR agonists. This study aimed to determine whether DOR activation is sufficient and necessary to mediate opioid-adrenergic synergistic interactions in the spinal cord. The antinociceptive effects of clonidine, [D-Ala 2 ]-deltorphin II (DeltII), morphine, and [D-Ala 2 , N-Me-Phe 4 , Gly-ol 5 ]-enkephalin (DAMGO) were evaluated using the substance P (SP) behavioral assay in wild type (WT) and DOR-knockout (KO) mice. Opioid-adrenergic drug interactions were evaluated after spinal coadministration of clonidine with DeltII, morphine, or DAMGO. Isobolographic analyses of dose-response curves determined whether interactions were synergistic or additive. The absence of DeltII antinociceptive efficacy in DOR-KO confirmed its selectivity in the SP assay. Although DeltII1clonidine interacted synergistically in WT mice, no interaction with clonidine was observed in DOR-KO mice. Clonidine was synergistic with morphine in both mouse strains. DAMGO did not synergize with clonidine in either strain. These findings confirm that although other opioid receptors can interact synergistically with a 2 AR agonists, DOR is sufficient for spinal opioid-adrenergic interactions.
Introduction
Patients with acute or chronic pain need better analgesic therapies to provide currently unmet pain relief. Opioid and a 2 -adrenergic receptor (a 2 AR) agonists are potent analgesic drugs, but their use is limited by their side effects or lack of efficacy in certain clinical conditions. Compared with the analgesic effects of drugs acting independently, analgesic synergy arising from drug combinations is advantageous because it produces adequate analgesia at lower doses, which can potentially reduce side effects and tolerance (Walker et al., 2002) . Pain management using opioid-a 2 AR agonist combinations reduces side effects associated with both a 2 AR and opioid treatments (Eisenach et al., 1994) , and such combinations may also be effective in treating chronic pain conditions with reduced opioid sensitivity (Eisenach et al., 1995) . In rodents, the opioid agonist morphine and the a 2 AR agonist clonidine synergize when coadministered at the spinal level, suggesting that beneficial opioid-adrenergic drug interactions occur at the spinal cord (Alguacil and Morales, 2004) . The clinical benefits of opioid-adrenergic combinations remain largely underexploited because the development of new therapies taking advantage of the synergistic interaction is hindered, in part, by a lack of understanding of the underlying mechanism.
To gain mechanistic insight, it is necessary to know the receptor subtypes required for synergy. Opioid agonists can mediate their analgesic action at the spinal cord by activating the delta-(DOR), mu-(MOR), and kappa-opioid receptor subtypes. [D-Ala 2 ]-Deltorphin II (DeltII), a DOR-selective peptide agonist, can synergize with the a 2 AR agonists clonidine , 6 -diethylphenylamino)-2-imidazoline hydrochloride] (Stone et al., 2007) , moxonidine (Fairbanks et al., 2000 (Fairbanks et al., , 2002 , and UK 14,304 (5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline) (Stone et al., 1997) when coadministered in rodents at the spinal cord. Similarly, another DOR-selective agonist, [D-Pen 2 ,D-Pen 5 ] enkephalin (DPDPE), has been shown to synergize with clonidine (Ossipov et al., 1990b; Roerig et al., 1992) , norepinephrine (Roerig et al., 1992) , and UK 14,304 (Guo et al., 2003) , and this latter synergistic interaction persists in MOR-KO mice (Guo et al., 2003) . Thus, opioid-adrenergic interactions resulting in analgesic synergy are possible when activating DOR and can occur in the absence of MOR. However, reports that DeltII and DPDPE retain their antinociceptive action in DOR-KO mice and that MOR mediates this effect questions the selectivity of DOR agonists (Scherrer et al., 2004; van Rijn et al., 2012) . This could mean that opioid-adrenergic synergistic interactions studied with DOR agonists are mediated by MOR and therefore justify further evaluation of the role of DOR in these interactions.
Morphine has been shown to interact synergistically with the a 2 AR agonists clonidine (Ossipov et al., 1990a; Roerig et al., 1992; Fairbanks and Wilcox, 1999b) , moxonidine (Fairbanks et al., 2000) , norepinephrine (Roerig et al., 1992) , and ST-91 (Monasky et al., 1990) . The antinociceptive effect of morphine is considered to be MOR mediated (Matthes et al., 1996) , which is consistent with its relative selective affinity for MOR in expression systems (Raynor et al., 1994) . Taken together, these studies would suggest that MOR mediates morphine's synergistic interactions with a 2 AR agonists. However, interactions between MOR and DOR have been shown to modulate morphine response in vivo and in vitro (Costantino et al., 2012) . For example, the cellular response after morphine treatment is more potent in cells coexpressing MOR and DOR rather than MOR alone (Yekkirala et al., 2010) . Furthermore, DOR-selective ligands potentiate morphine analgesia in vivo (Gomes et al., 2004) , and DOR is involved in the development of analgesic tolerance to morphine (Zhu et al., 1999) . Morphine also upregulates the expression of surface DOR through its action at the MOR (Cahill et al., 2001; Morinville et al., 2003; Gendron et al., 2006) . It is currently unknown whether DOR participates in morphine's synergistic interaction with a 2 AR agonists.
The aim of this study was to disambiguate the role of DOR in the synergistic interaction between opioid and a 2 AR agonists administered spinally. Therefore, we determined whether DOR activation is sufficient to produce synergy and whether DOR modulates MOR-mediated synergistic interactions with clonidine, the only a 2 AR agonist approved for epidural analgesic use. The antinociceptive interaction between clonidine and DeltII, morphine, or the MOR-specific agonist DAMGO was compared between wild-type (WT) and DOR-KO mice, which have a genetic deletion in the Oprd1 gene (Filliol et al., 2000) . We observed that the synergistic interaction between DeltII and clonidine required DOR. In contrast, the interaction between morphine and clonidine remained synergistic in DOR-KO mice, and DAMGO failed to synergize with clonidine in either strain. Our results demonstrate that DOR is sufficient, but not necessary, to mediate opioid-a 2 adrenergic analgesic synergy at the spinal cord.
Materials and Methods
Animals. Mice with a targeted gene deletion introducing a genetic deletion in exon 1 of the delta-opioid receptor gene (Oprd1) were developed on a mixed C57Bl/6ÂFVB/129 background (Filliol et al., 2000) . Congenic mice backcrossed to a standard C57Bl/6 background were obtained from The Jackson Laboratory (B6.129S2-Oprd1 tm1 Kff/ J, stock #007557; Bar Harbor, ME). Mice with a targeted gene deletion introducing a premature stop codon in the third transmembrane domain of the a 2A AR gene (Adra2a) were developed on a mixed C57Bl/ 6ÂFVB/129 background (Altman et al., 1999) . Congenic mice backcrossed to a standard C57Bl/6 background were obtained from The Jackson Laboratory (stock #004367). Commercially available C57BL/ 6 mice (Charles River Laboratories, Quebec, Canada) were purchased and used as wild type (WT). All strains were bred in house, and genotyping controls were performed on parent breeders to monitor the stability of the colony.
Mice were maintained on a regular 12-hour light/dark cycle and given access to food and water ad libitum. Aged-matched 3-to 6-monthold WT, DOR-KO, and a 2A AR-KO males were used in this study, and experimenters were blind to both genotype and treatment. All procedures were approved by the Animal Care Committee at McGill University and conformed to the ethical guidelines of the Canadian Council on Animal Care.
Drugs. Substance P (SP; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-LeuMet-NH 2 ) was purchased from AnaSpec (Fremont, CA), and concentrated stocks were dissolved in acidified saline (0.9% NaCl, 0.05 M acetic acid). ]-deltorphin II (DeltII; R&D Systems) was dissolved in acidified saline. Drug stocks were diluted in saline to working concentrations.
Pharmacological Treatment. Intrathecal drug administration was done by direct lumbar puncture in a volume of 5 ml according to the method of Hylden and Wilcox (1980) in conscious mice. DeltII, morphine, DAMGO, and clonidine doses are expressed as total nanomoles or picomoles, and drug combination doses are graphed as total drug doses (i.e., the sum of both drugs) in 5 ml and expressed in nanomoles. Drugs were administered simultaneously with 15 ng of SP in a single 5-ml volume. After randomization, each mouse was reused with a minimum of 5 days between testing session to allow for drug wash out.
SP Behavioral Assay. The antinociceptive action of single drugs and their combination was tested in the substance P (SP) behavioral assay developed by Hylden and Wilcox (1981) . In brief, 15 ng of SP was administered intrathecally alone (control) or coadministered with a single drug or a drug combination in a volume of 5 ml. The number of caudally directed biting, licking, and scratching behaviors were counted for 1 minute and results are expressed as the percent inhibition of SP-induced behaviors.
Dose-Response Analysis. Dose-response graphs were generated with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA). A minimum of five animals was used per dose, and each dose point is expressed as the mean percent inhibition with S.E.M. For drug combinations, the dose-response curve was graphed according to the dose of clonidine present in the mixture. Drugs had to reach at least 50% inhibition to be considered effective. ED 50 values and 95% confidence intervals (CI) were calculated using a minimum of three doses in the linear portion of each dose-response curve following the method of Tallarida and Murray (1987) . Statistical comparisons of potencies based on the confidence limits of the ED 50 values were calculated to obtain the relative potency ratio between two drugs.
Isobolographic Analysis. Drug combination ratios were chosen according to the relative potency of each drug by determining an approximately equally effective potency ratio between the agonists based on their respective ED 50 values. When two drugs were equally potent, they were mixed in a 1:1 (i.e., equieffective and equimolar) ratio. If a drug was 10 times more potent than the other, drugs were mixed in a 1:10 (i.e., equieffective) ratio. Because the relative drug potency of the drug pairs used in this study differed between WT and DOR-KO mice, different drug ratios were tested in each strain, and the experimental ED 50 value for the drug combination was determined. To test for interactions between agonists, the ED 50 values and S.E.M. of all dose-response curves were arithmetically arranged around the ED 50 value using equation [ln(10) ☓ ED 50 ] ☓ (S.E. of log ED 50 ) (Tallarida, 1992) . This manipulation was required to perform an isobolographic analysis, the appropriate method to evaluate if an interaction is synergistic, additive, or subadditive (Tallarida, 1992) . When testing an interaction between two drugs, a theoretical additive ED 50 value is calculated for the combination based on the doseresponse curve of each drug administered separately. This theoretical value is then compared by a Student's t test with the observed experimental ED 50 value of the combination. An interaction is considered synergistic if the experimental ED 50 is significantly less (P , 0.05) than the calculated theoretical additive ED 50 .
Visualization of drug interactions can be facilitated by graphical representation of isobolographic analysis. This representation depicts the ED 50 value of each drug as the x-or y-intercept. The line connecting these two points depicts the dose combination expected to yield 50% efficacy if the interaction is purely additive and is called the theoretical additive line. The theoretical additive ED 50 is determined mathematically and plotted on this line with its CI spanning perpendicularly from the line. The experimental ED 50 for the combination is plotted at the corresponding x, y coordinates along with its 95% confidence interval for comparison with the theoretical additive ED 50 value.
All dose-response and isobolographic analyses were performed with the FlashCalc 4.5.3 pharmacological statistics software package generously supplied by Dr. Michael Ossipov.
Results
Comparable SP-Evoked Nocifensive Behaviors Are Measured in WT and DOR-KO Mice. We used the SP behavioral assay to measure the antinociceptive effect of opioid agonists and clonidine at the spinal level. Intrathecal administration of SP induces a characteristic set of behaviors (biting, licking, and scratching) directed at the abdomen and hind portion of the mouse receiving the exogenous SP (Hylden and Wilcox, 1981) . Analgesic drugs acting at the spinal cord inhibit these nocifensive behaviors in a dose-dependent manner. There was no significant difference in SP-induced behaviors between WT (37 6 4, n 5 13), DOR-KO (34 6 3, n 5 22), and a 2A AR-KO (29 6 3, n 5 18) mice (unpaired one-way ANOVA, P . 0.05) upon intrathecal injection of 15 ng SP. Thus, there is no strain difference in sensitivity to SP nociception.
Antinociceptive Action of Spinally Administered DeltII, DAMGO, Morphine, and Clonidine in WT, DOR-KO, and a 2A AR-KO Mice. DeltII, morphine, DAMGO, and clonidine were administered intrathecally in both WT and DOR-KO mice. All drugs inhibited SP-induced nocifensive behaviors in a dose-dependent manner ( Fig. 1; Table 1 ), except for DeltII, which was effective in WT but not DOR-KO mice (Fig. 1B) . Clonidine inhibition of SP-induced behaviors was 3-fold more potent in DOR-KO mice compared with WT mice (Fig. 1A ; Table 1 ). The inhibitory action of morphine was similar in both WT and DOR-KO mice at lower doses. As morphine dose increases, its efficacy was reduced in DOR-KO mice compared with WT mice (Fig. 1C) . Nevertheless, there is no significant potency difference between WT and DOR-KO mice (Table 1 ). No strain difference was observed with the MOR agonist DAMGO (Fig. 1D) . In a 2A AR-KO mice, clonidine efficacy was reduced to less than 50% inhibition and potency was reduced by 20-fold compared with WT mice (Fig. 1E) . Together, these data indicate that DOR mediates DeltII antinociception in the SP assay, morphine and clonidine antinociception are slightly altered in DOR-KO mice, and clonidine antinociception is largely mediated by the a 2A AR.
Deltorphin II-Clonidine Spinal Antinociceptive Synergy Requires DOR. We tested the DOR-selective agonist DeltII and clonidine alone or in combination in the SP behavioral assay in WT and DOR-KO mice. In WT mice, DeltII and clonidine inhibited SP-induced nocifensive behaviors in a dose-dependent manner with similar potency (Fig. 2A ). Thus, we tested DeltII in combination with clonidine at an equieffective ratio that also corresponds to an equimolar drug ratio (1:1). The inhibition of SP-induced behaviors by the drug combination shifted the dose-response curve leftward. Isobolographic analysis revealed that the experimental ED 50 value of the drug combination was significantly lower than the theoretical additive ED 50 value; the drug interaction is therefore synergistic (Fig. 2B ; Table 2 ). Table 1 .
Role of DOR in Opioid-Adrenergic Analgesic Synergy
In DOR-KO mice, DeltII was ineffective in the SP assay at all doses tested. We therefore used the same equimolar (1:1) drug ratio to compare the DeltII1clonidine interaction in DOR-KO mice that was used in the WT mice. Because DeltII was not efficacious, isobolographic analysis was not possible. However, the inhibition of SP-induced behaviors by the DeltII1clonidine combination was equivalent to clonidine alone, i.e., DeltII did not shift the clonidine dose-response curve in DOR-KO mice, suggesting that there is no interaction between DeltII and clonidine in DOR-KO mice (Fig. 2C) .
Morphine-Clonidine Spinal Antinociceptive Synergy Persists in the Absence of DOR. Because DOR activation is sufficient to produce synergy using a DOR-selective agonist, we assessed its necessity for the synergistic interaction between morphine and clonidine.
In WT mice, spinally administered morphine and clonidine inhibited SP-induced behaviors in a dose-dependent manner. Calculated ED 50 values obtained for each drug were within one order of magnitude; hence, we combined morphine 1 clonidine at an equieffective and equimolar (1:1) ratio. The drug combination also inhibited SP behaviors in a dosedependent manner, and the dose-response curve was shifted to the left compared with the single doses (Fig. 3A) . The isobolographic analysis demonstrated that the morphine 1 clonidine interaction in WT mice was synergistic ( Fig. 3B ; Table 2 ).
We then assessed the interaction between morphine and clonidine in DOR-KO mice. Because the difference in ED 50 values between morphine and clonidine in DOR-KO mice was more than one order of magnitude (Table 1) , we tested an equieffective drug ratio of 1 part clonidine 1 10 parts morphine (1:10). The drug combination dose-dependently inhibited SP behaviors in DOR-KO mice and the doseresponse curve was shifted to the left compared with each drug alone (Fig. 3C) . Isobolographic analysis showed that the experimental ED 50 value is significantly lower than the theoretical additive ED 50 value (Fig. 3D) , indicating that the interaction is synergistic (Table 2) .
Taken together, these results show that equieffective doses of morphine and clonidine interact synergistically in both WT and DOR-KO mice.
DAMGO-Clonidine Interaction Is Additive in Both WT and DOR-KO Mice. The retention of morphine 1 clonidine synergy in DOR-KO mice suggests that opioidadrenergic synergy can be mediated by MOR in the absence of DOR. To understand the requirements for MOR-mediated synergy with clonidine, we tested the combination of clonidine with the MOR-selective peptide agonist DAMGO in WT and DOR-KO mice. In WT mice, DAMGO inhibited SP-induced behaviors with an ED 50 value 120-fold more potent than clonidine (Table 1 ). Therefore, we tested a combination of clonidine and DAMGO at a 100:1 ratio, which also inhibited SP-induced behaviors in a dose-dependent manner (Fig. 4A) . The isobolographic analysis revealed that this interaction was additive ( Fig. 4B ; Table 2 ).
The potency difference between DAMGO and clonidine in DOR-KO mice required the use of a 1:10 drug ratio corresponding to equieffective doses in this strain. The resulting drug interaction was also additive (Fig. 4 , C and D; Table 2 ).
Discussion
This study addressed the role of DOR in spinal opioidadrenergic synergistic interactions. We first compared the antinociceptive response of clonidine, DeltII, morphine, and DAMGO between WT and DOR-KO mice in the SP behavioral assay. The observed lack of DeltII efficacy in DOR-KO mice confirms its DOR selectivity in the SP behavioral assay. The addition of clonidine to DeltII resulted in a synergistic interaction in WT but not in DOR-KO mice. In contrast, a synergistic interaction between clonidine and morphine was observed in both strains, and the interaction between clonidine and the MOR-selective agonist DAMGO was additive in both strains. These data demonstrate that DOR is sufficient, but not necessary, for opioid-adrenergic synergistic interaction at the spinal cord. Mechanisms Mediating Opioid-Adrenergic Synergy. Opioid-adrenergic synergy could arise from pharmacokinetic interactions. In addition to their antinociceptive effects, a 2 AR agonists such as clonidine have a local vasoconstrictive effect (Asada and Lee, 1992; Iida et al., 1999 ) that can reduce drug clearance from the site of injection. Clonidine could therefore enhance the effect of another drug by maintaining it at a high local drug concentration. Following this logic, clonidine should interact synergistically with other drug classes. For example, in a postoperative pain model, clonidine interacts synergistically after intrathecal injection with gabapentin and with an allosteric adenosine receptor modulator (Cheng et al., 2000; Obata et al., 2004) . However, reports of synergistic interactions with some, but not all, opioids makes altered drug clearance an unlikely mechanism. Furthermore, ST-91, an a 2 AR agonist with hypertensive effects (Yasuoka and Yaksh, 1983; Nagasaka and Yaksh, 1990) , interacts synergistically with morphine but does not affect morphine clearance from the spinal cord (Monasky et al., 1990) . Thus, the pharmacokinetic actions of a 2 AR agonists are unlikely mediators of spinal opioid-adrenergic synergy.
The diffusion of intrathecally administered drugs to supraspinal sites is negligible over a short period of time (Hylden and Wilcox, 1980) . Rather, intrathecally administered compounds act locally on the spinal cord and nociceptors, which have opioid and adrenergic receptors capable of inhibiting the transmission of afferent nociceptive signals.
Pharmacodynamic interactions between opioids and a 2 AR agonists resulting in analgesic synergy could involve spinal intercellular or intracellular mechanisms. Because spinal MOR, DOR, and a 2 AR are distributed on both primary afferent and Table 2 .
Role of DOR in Opioid-Adrenergic Analgesic Synergy spinal neurons (Stone et al., 1998; Wall et al., 2006) , it is possible that the cumulated neuronal inhibition in the nociceptive circuit is supra-additive. Synergistic interactions could also result from the coexpression of opioid and adrenergic receptors in the same cells where their simultaneous activation results in synergistic output as proposed by Overland et al. (2009) . DOR is Sufficient to Produce Opioid-Adrenergic Synergy. Previous studies have shown that spinal coadministration of the DOR-selective peptide agonists DPDPE and DeltII with clonidine results in a synergistic interaction in both the tail-flick and SP behavioral assays (Ossipov et al., 1990b; Roerig et al., 1992; Roerig, 1995; Overland et al., 2009 ). These interactions persist in MOR-KO mice, suggesting that MOR is not required (Guo et al., 2003) . However, the analgesic effects of DeltII have been attributed to MOR in some behavioral assays such as the tail-flick assay (Scherrer et al., 2004; van Rijn et al., 2012) , raising the possibility that these synergistic interactions with a 2 AR agonists are MOR mediated rather than DOR mediated. In the current study, DeltII antinociception was absent in DOR-KO mice, validating the use of the SP behavioral assay as a tool to examine the role of DOR in synergistic interactions. As a result, the absence of DeltII-clonidine synergy in DOR-KO mice confirms that DOR activation is sufficient to interact synergistically with a 2 AR agonists. Assays should be carefully validated when studying DOR-mediated synergistic interactions because the current findings may not generalize to different assays.
In the spinal cord, clonidine has been shown to interact with both a 2 AR and imadazoline binding sites, but the antinociceptive effect of clonidine is mediated by a 2 AR rather than imadazoline receptors (Monroe et al., 1995a,b) . Our data further suggest that the a 2A AR is a key mediator of clonidine antinociception. This observation is consistent with previous studies showing the loss of clonidine antinociceptive efficacy observed in mice expressing a dysfunctional a 2A AR (Fairbanks and Wilcox, 1999a) . The a 2A AR is also necessary for analgesic synergy between DeltII and the a 2 AR agonist UK 14,304 (Stone et al., 1997) . DOR and a 2A AR can both exert their analgesic action by inhibiting transmitter release from primary afferent terminals (Glaum et al., 1994; Kawasaki et al., 2003) . Data suggest that the synergistic interaction between DeltII and clonidine is maintained at the level of the primary afferent nerve terminal; for example, this drug combination inhibited KCl-induced CGRP release synergistically from spinal cord slices . Thus, peptidergic primary afferent neurons are a potential site of action of opioid-adrenergic synergy. We demonstrated that DOR and a 2A AR receptors are coexpressed in primary afferent neurons and highly colocalize in SP-immunoreactive neurons and isolated nerve terminals (Riedl et al., 2009) . Although the localization of DOR in SP neurons is debated (Scherrer et al., 2009; Wang et al., 2010) , the above-mentioned physiologic and anatomic evidence support the presence of DOR and a 2A AR in peptidergic neurons where they would be positioned to inhibit neurotransmitter release in a synergistic manner. Table 2 .
DOR Is Not Necessary to Mediate Morphine-Clonidine Synergy. The synergistic interaction between morphine and clonidine is well documented in rodents using different assays . Because the interaction is stronger when the drugs are administered intrathecally compared with intravenously, it has been proposed to be mediated largely at the level of the spinal cord (Ossipov et al., 1990a) . Spinal MOR and DOR can interact together and form heteromeric complexes with altered signaling properties upon morphine treatment (Costantino et al., 2012) , which led us to hypothesize that the morphine1clonidine synergistic interaction may require DOR. Our data demonstrate that in DOR-KO mice, a synergistic interaction between morphine and clonidine is still present, allowing us to conclude that DOR is not the only opioid receptor able to mediate opioid-adrenergic analgesic synergistic interactions. Because morphine is not efficacious in the SP behavioral assay in MOR-KO compared with WT mice (Guo et al., 2003) , the activation of MOR likely mediates the synergistic interaction between morphine and clonidine.
Synergistic Interactions Involving MOR are Assay Dependent and Ligand Biased. Coactivation of MOR with an a 2 AR agonist produces different interactions depending on the experimental conditions and agonists used. Although the interaction between DAMGO and clonidine is either additive (Fig. 4) or subadditive in the SP behavioral assay (Roerig et al., 1992) , this drug combination is synergistic in the tailflick assay (Roerig, 1995) . Furthermore, the combination of DAMGO with different a 2 AR agonists in the SP behavioral assay can produce either synergistic (Stone et al., 1997) or subadditive (Fairbanks et al., 2000) interactions. Thus, depending on the assay and ligands used, MOR activation may or may not contribute to spinal opioid-adrenergic synergistic interactions.
The contrasting results obtained using two agonists that activate MOR suggest the mechanism underlying these interactions may involve ligand-biased signaling. Morphine and DAMGO engage different downstream signaling cascades upon binding and activation of MOR. Although DAMGO produces robust b-arrestin-dependent MOR translocation and desensitization, morphine produces PKC-dependent desensitization (Johnson et al., 2006; Chu et al., 2008) . In cultured sensory neurons, DAMGO cross-desensitizes clonidine's inhibition of Ca 21 currents and produces cointernalization of MOR with a 2A AR through the b-arrestin 2 and p38 MAPK signaling pathway; morphine produces neither of these effects (Tan et al., 2009) . This cross-desensitization between DAMGO and clonidine could explain why their interaction is typically not synergistic in vivo. On the other hand, morphine activates PKC« in HEK 293 cells expressing MOR, but not DAMGO (Chu et al., 2010) . It is noteworthy that synergistic interactions arising from morphine-clonidine (Wei and Roerig, 1998) and DeltII-clonidine combinations are PKC dependent. This signaling event is unconventional for the opioid and adrenergic receptors that are usually coupled to the pertussis toxin-sensitive G i/o signaling pathway. Intrathecal pertussis toxin treatment decreases morphine and clonidine potency but does not block their synergistic interaction (Roerig and Howse, 1996; Wei et al., 1996) . Therefore, morphine-clonidine synergy probably arises from a signaling pathway independent of the pathways activated by the drugs alone and involves PKC activation. The direct interaction between MOR and the a 2A AR demonstrated in expression systems support the hypothesis that these interactions could occur via heteromeric G protein-coupled receptor interactions (Vilardaga et al., 2008) .
Conclusion
Our data support that activation of DOR is sufficient, but not necessary, to produce analgesic synergy when a 2 AR are also activated. Therefore, the synergistic interaction between different opioid-a 2 adrenergic agonists is mediated via different opioid receptor pathways; one of these pathways uses DOR and another pathway is likely using MOR.
Currently clinically used opioids act through MOR, which mediates both their analgesic and side effects. Despite the benefits of mixing morphine and clonidine, side effects are still an issue for some patients. We therefore encourage the development and use of DOR-selective ligands in combination with a 2 AR agonists as an alternative to currently available opioid agonists.
